Note 5 - U.S. Department of Defense Contract	12 Months Ended
Dec. 31, 2017
Notes to Financial Statements
Long-term Contracts or Programs Disclosure [Text Block]	5. U.S. Department of Defense Funding On May 11, 2015, the Company entered into an award contract (referred to as the DoD Contract) supported by the Clinical and Rehabilitative Medicine Research Program, or CRMRP, of the United States Army Medical Research and Materiel Command, or the USAMRMC, within the U.S. Department of Defense, or the DoD, in which the DoD agreed to provide up to $17.0 million to the Company in order to support the development of DSUVIA (sufentanil sublingual tablet, 30 mcg), a proprietary, non-invasive, single-use tablet in a disposable, pre-filled single-dose applicator, or SDA, for the treatment of moderate-to-severe acute pain. Under the terms of the DoD Contract, the DoD has reimbursed the Company for costs incurred for development, manufacturing, regulatory and clinical costs outlined in the DoD Contract, including reimbursement for certain personnel and overhead expenses. The period of performance under the DoD Contract began on May 11, 2015. The DoD Contract gives the DoD the option to extend the term of the DoD Contract and provide additional funding for the research. On March 2, 2016, the DoD Contract was amended to approve enrollment of additional patients in the SAP302 study, approve the addition of the SAP303 study, and extend the DoD Contract period of performance by four months from November 10, 2016 to March 9, 2017, to accommodate the increased SAP302 patient enrollment and the SAP303 study. The costs for these changes were included within the current DoD Contract value. On March 9, 2017, the DoD Contract was amended to incorporate additional activities including the development and testing of packaging changes; additional stability testing; and preparation for any FDA advisory committee meeting for DSUVIA. The amendment also extends the DoD Contract period of performance by 11 months through February 28, 2018 to accommodate these additional activities. At December 31, 2017, the additional activities as outlined under the DoD Contract through February 28, 2018 were substantially complete. On February 28, 2018, the DoD contract was amended to incorporate additional services in the amount of $0.5 million and to extend the contract period by twelve months through February 28, 2019. If DSUVIA is approved by the FDA, the DoD has the option to purchase a certain number of units of commercial product pursuant to the terms of the DoD Contract. Revenue is recognized based on expenses incurred by the Company in conducting research and development activities, including overhead, as set forth in the agreement. Revenue attributable to the work performed under the DoD Contract, recorded as Contract and other revenue in the Consolidated Statements of Comprehensive Loss, was $0.9 million, $10.9 million and $4.4 million for the years ended December 31, 2017, 2016 and 2015, respectively.

U.S. Department of Defense Funding

May 11, 2015,

the Company entered into an award contract (referred to as the DoD Contract) supported by

the Clinical and Rehabilitative Medicine Research Program, or CRMRP, of the United States Army Medical Research and Materiel Command, or the USAMRMC, within the U.S. Department of Defense, or the DoD, in which the DoD

agreed to provide up to

$17.0

million to the Company in order to support the development of

DSUVIA (sufentanil sublingual tablet,

mcg), a proprietary,

non-invasive, single-use tablet in a disposable, pre-filled single-dose applicator, or SDA, for the treatment of moderate-to-severe acute pain.

Under the terms of the DoD Contract, the DoD has reimbursed the Company for costs incurred for development, manufacturing, regulatory and clinical costs outlined in the DoD Contract, including reimbursement for certain personnel and overhead expenses. The period of performance under the

DoD Contract began on

May 11, 2015.

The

DoD Contract gives the DoD the option to extend the term of the

DoD Contract and provide additional funding for the research.

March 2, 2016,

the DoD Contract was amended

to approve enrollment of additional patients in the

SAP302

study, approve the addition of the

SAP303

study, and extend the DoD Contract period of performance by

four

months from

November 10, 2016

March 9, 2017,

to accommodate the increased

SAP302

patient enrollment and the

SAP303

study. The costs for these changes were included within the current DoD Contract value. On

March 9, 2017,

the DoD Contract was amended to incorporate additional activities including the development and testing of packaging changes; additional stability testing; and preparation for any FDA advisory committee meeting for DSUVIA. The amendment also extends the DoD Contract period of performance by

months through

February 28, 2018

to accommodate these additional activities. At

December 31, 2017,

the additional activities as outlined under the DoD Contract through

February 28, 2018

were substantially complete. On

February 28, 2018,

the DoD contract was amended to incorporate additional services in the amount of

$0.5

million and to extend the contract period by

twelve

months through

February 28, 2019.

DSUVIA is approved by the FDA, the DoD has the option to purchase a certain number of units of commercial product pursuant to the terms of the

DoD Contract.

Revenue is recognized based on expenses incurred by the Company in conducting research and development activities, including overhead, as set forth in the agreement.

Revenue attributable to the work performed under the DoD Contract, recorded as Contract and other revenue in the Consolidated Statements of Comprehensive Loss, was

$0.9

million,

$10.9

million and

$4.4

million for the years ended

December 31, 2017,

2016

and

2015,

respectively.